Clinical Research Directory
Browse clinical research sites, groups, and studies.
NAD Augmentation in Diabetes Kidney Disease
Sponsor: Brigham and Women's Hospital
Summary
A phase 2a trial randomized, double-blind, placebo-controlled, parallel group trial to determine whether NMN administration improves DKD, as indicated by a significantly greater reduction in UACR compared with placebo administration. Eligible participants will be randomized to receive either 1000 mg NMN or placebo twice daily.
Official title: NAD Augmentation to Treat Diabetes Kidney Disease: A Randomized Controlled Trial
Key Details
Gender
All
Age Range
60 Years - Any
Study Type
INTERVENTIONAL
Enrollment
140
Start Date
2023-04-13
Completion Date
2027-03-31
Last Updated
2026-02-18
Healthy Volunteers
No
Conditions
Interventions
Investigational Product - MIB 626
The eligible participants will be assigned to receive either NMN or placebo using concealed block randomization in a 1:1 ratio, stratified by sex (male, female), age (60 to 75, \>75 years) and trial site. The randomization list will be generated by the unblinded biostatistician using the software R (www.r-project.org), and deployed in a secure, centralized web-based application accessible to study staff following confirmation of a participant's eligibility.
Placebo
Placebo - Participants randomized to placebo will receive Matching placebo tablets will be provided by Metro International Biotech, LLC.
Locations (1)
Brigham and Women's Hospital
Boston, Massachusetts, United States